Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Anktiva plus BCG outperforms BCG alone in newly treated high-risk bladder cancer – ImmunityBio

Written by | 18 Nov 2026 | Internal Medicine

ImmunityBio, Inc. announced positive results from the final analysis of the primary endpoint in Cohort A of QUILT-2.005 (NCT02138734), a randomized, controlled, registrational trial evaluating intravesical Anktiva (nogapendekin alfa inbakicept-pmln/N-803) in combination with Bacillus Calmette-Guérin (BCG) versus BCG alone in patients with BCG-naïve, high-grade non-muscle invasive bladder cancer (NMIBC). The chemotherapy-free combination demonstrated a statistically significant improvement in efficacy compared with BCG alone in patients with carcinoma in situ (CIS), with or without papillary tumors.

The trial involved over 75 clinical trial sites with three largest enrolling sites at US Urology Partners, Dartmouth-Hitchcock, and University of California Los Angeles. Additional study details will be presented at an upcoming medical congress.

“For nearly 40 years, BCG has been the gold standard for patients newly diagnosed with high-risk NMIBC, with limited innovation in the frontline setting. For patients with carcinoma in situ with or without papillary tumors, the meaningful improvement in response rates when intravesical Anktiva is administered with BCG represents an important practice-changing advance. By improving responses earlier in the disease course, this combination has the potential to help more patients remain disease-free longer, avoid additional treatments.” – Christopher Pieczonka, M.D., Corporate Director of Clinical Research at U.S. Urology Partners and Global Principal Investigator of the QUILT-2.005 trial.

“As an NCI-designated Comprehensive Cancer Center, we are committed to advancing innovative research and clinical trials that have the potential to improve outcomes for patients. For patients with NMIBC, recurrence following standard-of-care BCG remains a significant challenge. This study was designed to investigate whether adding N-803 to BCG could increase the patient response rate and reduce the risk of early recurrence. We are proud to have contributed to this important research, which has the potential to reshape the treatment landscape for patients living with NMIBC.” – Einar F. Sverrisson, MD, Assistant Professor of Surgery at Dartmouth’s Geisel School of Medicine and urologist at Dartmouth Hitchcock Medical Center.

“These results build on the clinical findings observed in patients with BCG-unresponsive NMIBC and underscore the potential of Anktiva plus BCG to become the first chemotherapy-free immunotherapy combination to improve treatment outcomes for patients with BCG-naïve bladder cancer. The statistically significant improvement in efficacy supports our efforts to extend this therapeutic approach to patients earlier in their treatment journey. We are grateful to the patients, families and clinical teams who made this study possible.” – Patrick Soon-Shiong, M.D., Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio.

Safety of N-803 plus BCG versus BCG Alone

The most common treatment-emergent and treatment-related adverse events were consistent with those observed with BCG alone. No treatment-related deaths were reported.

About the QUILT-2.005 Study

QUILT-2.005 (NCT02138734) is a randomized, controlled registrational trial comparing the intravesical chemotherapy-free combination of Anktiva (nogapendekin alfa inbakicept-pmln) with BCG versus BCG alone in patients with BCG-naïve NMIBC. BCG-naïve patients are those receiving BCG-based therapy for the first time, representing an earlier stage of treatment than the BCG-unresponsive population for which Anktiva is currently approved. Enrollment was completed in February 2026 with 370 randomized patients. Following a protocol-specified interim review in March 2026, the IDMC determined that no additional enrollment was required to maintain the study’s prespecified statistical power. Database lock occurred on October 20, 2026 and the supplemental BLA is on track to be submitted to the FDA before year end 2026. Full details can be found on clinicaltrials.gov.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.